CLAIMS

We claim :

1. A compound selected from those of formula (I) :



(I)

wherein

- ✓ R_1, R_2, R_3 and R_4 independently represent hydrogen, halogen or alkyl, alkoxy, hydroxy, alkylthio, mercapto, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl,
  or, taken in pairs, form together with the carbon atoms to which they are bonded a phenyl ring or an aromatic heterocycle having from 5 to 7 ring members and containing from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur,

- ✓ L_1 and L_2 each represents hydrogen or together form $-CH_2-CH_2-$,

- ✓ X_1, attached at the 2 or 3 position of the aromatic ring, represents a bond, and in that case X_2 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),
  or,
  X_1 and X_2, together with two adjacent carbon to which they are bonded in the 2, 3 or 4 position of the aromatic ring, form (C_4-C_7)cycloalkyl wherein one or two $-CH_2-$ of the cycloalkyl ring are optionally replaced by oxygen or NH (optionally substituted by alkyl) and wherein one carbon of the cycloalkyl ring is substituted by G,

- ✓ X_3 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),

- ✓ G represents a group selected from :



G_1



G_2



G_3 and



G_4 ,

wherein :

- ✓ the broken lines indicate the optional presence of a double bond,

- ✓ Alk represents linear or branched (C_1-C_6)alkylene wherein, when G_1 or G_2 contains imidazoline, the group Alk- is attached at the 2 position of the ring,

- ✓ n is 0 or 1,

- ✓ T_3 represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl,

- ✓ T_4 represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl,

wherein :

- the term "alkyl" denotes linear or branched group containing from 1 to 6 carbon,
- the term "alkoxy" denotes linear or branched alkyl-oxy containing from 1 to 6 carbon,
- the term "aryl" denotes phenyl, naphthyl or biphenyl,

- the term "heteroaryl" denotes an aromatic monocyclic group, or a bicyclic group in which at least one of the rings is aromatic, each group containing from 5 to 11 ring members and from 1 to 5 hetero atoms selected from nitrogen, oxygen and sulphur,
- the expression "optionally substituted" associated with aryl, arylalkyl, heteroaryl and heteroarylalkyl denotes that those groups are unsubstituted or substituted on the cyclic moiety by one or more halogen and/or alkyl, alkoxy, hydroxy, mercapto, alkylthio, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl, wherein heteroaryl and heteroarylalkyl may in addition be substituted by oxo,

enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

2. Compounds of claim 1, wherein L_1 and L_2 each represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

3. Compounds of claim 1, wherein L_1 and L_2 together form $-CH_2-CH_2-$, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

4. Compounds of claim 1, wherein R_1 and R_4 each represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

5. Compounds of claim 1, wherein R_2 and R_3 are selected from halogen and alkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

6. Compounds of claim 1, wherein X_1 is attached at the 2 position of the phenyl ring, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

7. Compounds of claim 1, wherein X_1 represents a bond and X_2 represents halogen or alkyl or alkoxy, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

8. Compounds of claim 1, wherein X_3 represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

9. Compounds of claim 1, wherein R_3 and R_4 together with carbon to which they are bonded form a phenyl ring and L_1 and L_2 together form $-CH_1-CH_2-$, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

10. Compounds of claim 1, wherein G is selected from :



G'$_1$ G''$_1$ G'$_2$ G'$_3$

wherein T'3 will be more especially optionally substituted heteroaryl or optionally substituted heteroarylalkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

11. Compounds of claim 1, wherein X_1 and X_2, together with two carbon in the 2 and 3 position of the aromatic ring to which they are bonded, form (C_4-C_7)cycloalkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

12. Compound of formula (I) that is *N*-(3-chloro-4-methylphenyl)-*N'*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

13. Compound of formula (I) that is *N*-[4-chloro-3-(4,5-dihydro-1*H*-imidazol-2-ylamino) phenyl]-*N'*-(3-chloro-4-methylphenyl)urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

14. Compound of formula (I) that is *N*-(3-chloro-4-methylphenyl)-*N'*-[2-(1H-imidazol-4-yl)-indan-5-yl]urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

15. Compound of formula (I) that is *N*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}-*N'*-(3,4-dimethylphenyl)urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

16. A method for treating an animal of human living body afflicted with a disease requiring as dual α_2/5-HT_{2c} antagonist comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said condition

17. A pharmaceutical composition comprising useful in the claim 16 method comprising as active ingredient one compound according to claim 1 in combination with one or more pharmaceutically acceptable, excipients or vehicles.